Lupus & antiphospholipid syndrome
Non-criteria antiphospholipid antibody profiles and thrombotic outcomes in a cohort of patients with systemic lupus erythematosus
Main finding · Major thrombosis, multivariate analysis (adjusted for age, sex, prednisone use, SLEDAI-2K and revised Sapporo lab criteria)Result — go to the resultOdds ratio 2.2 95% CI 1.1–4.5Authors' conclusion
In our multivariate analysis, IgG aPS/PT was associated with a modestly increased risk of thrombotic events.
Study context
- Population
- Patients with systemic lupus erythematosus (SLE) (ACR or SLICC classification criteria) in the SouThern Alberta Registry for Lupus EryThematosus; records reviewed March 2006–January 2021
- Participants
- 341 patients
- Exposure
- Non-criteria aPL positivity and thrombosis risk in SLE
- Revised Sapporo lab criterian = 59
- ≥1 positive non-criteria autoantibodyn = 142
- Outcome
- Major thrombotic event
Methodological detailsregistry-based, univariate and multivariate analysis
- Registry-based
- Univariate and multivariate analysis
Main finding
As reported in the abstract
Major thrombosis, multivariate analysis (adjusted for age, sex, prednisone use, SLEDAI-2K and revised Sapporo lab criteria)
Odds ratio
2.2
95% CI 1.1–4.5
IgG aPS/PT
OR 2.2 (95% CI 1.1–4.5)
Observational data: associations, not effects.
Further findings
Major thrombotic event by antibody profile
OR Revised Sapporo lab criteria 3.5 · ≥1 positive non-criteria autoantibody 1.6
95% CI Revised Sapporo lab criteria 1.9 to 6.3 · ≥1 positive non-criteria autoantibody 0.97 to 2.6
Major and all thrombotic events, univariate analysis
- IgG aPS/PT and IgG aβ2GP1-D1 were associated with major and all thrombotic events
Original publication
Non-criteria antiphospholipid antibody profiles and thrombotic outcomes in a cohort of patients with systemic lupus erythematosus. Lupus Sci Med. Published 12 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →